全文获取类型
收费全文 | 10078篇 |
免费 | 558篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 187篇 |
妇产科学 | 240篇 |
基础医学 | 1352篇 |
口腔科学 | 445篇 |
临床医学 | 847篇 |
内科学 | 2696篇 |
皮肤病学 | 299篇 |
神经病学 | 1008篇 |
特种医学 | 300篇 |
外科学 | 1180篇 |
综合类 | 27篇 |
一般理论 | 2篇 |
预防医学 | 472篇 |
眼科学 | 133篇 |
药学 | 587篇 |
中国医学 | 27篇 |
肿瘤学 | 832篇 |
出版年
2024年 | 8篇 |
2023年 | 72篇 |
2022年 | 153篇 |
2021年 | 295篇 |
2020年 | 160篇 |
2019年 | 232篇 |
2018年 | 277篇 |
2017年 | 219篇 |
2016年 | 227篇 |
2015年 | 280篇 |
2014年 | 394篇 |
2013年 | 483篇 |
2012年 | 780篇 |
2011年 | 808篇 |
2010年 | 416篇 |
2009年 | 386篇 |
2008年 | 666篇 |
2007年 | 685篇 |
2006年 | 606篇 |
2005年 | 648篇 |
2004年 | 565篇 |
2003年 | 508篇 |
2002年 | 488篇 |
2001年 | 117篇 |
2000年 | 106篇 |
1999年 | 102篇 |
1998年 | 112篇 |
1997年 | 77篇 |
1996年 | 80篇 |
1995年 | 71篇 |
1994年 | 59篇 |
1993年 | 43篇 |
1992年 | 53篇 |
1991年 | 52篇 |
1990年 | 49篇 |
1989年 | 61篇 |
1988年 | 34篇 |
1987年 | 43篇 |
1986年 | 38篇 |
1985年 | 28篇 |
1984年 | 26篇 |
1983年 | 31篇 |
1982年 | 20篇 |
1981年 | 9篇 |
1980年 | 18篇 |
1979年 | 11篇 |
1976年 | 10篇 |
1974年 | 9篇 |
1973年 | 7篇 |
1968年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Existing asthma therapies are not always able to achieve disease control. The addition of tiotropium bromide to inhaled corticosteroids might be effective in improving disease outcome. This paper discusses the results of a study evaluating the effects of tiotropium bromide added to inhaled corticosteroids when compared to other regimens in patients with uncontrolled asthma. The addition of tiotropium to the current inhaled corticosteroid dose is comparable to the addition of salmeterol: both are more effective in achieving disease control versus doubling the inhaled corticosteroid dose. It is well worth investigating the effects of tiotropium in asthma that is not adequately controlled with higher doses of inhaled corticosteroids. 相似文献
992.
Incorvaia C Frati F Dell'Albani I Robino A Cattaneo E Mauro M David M Qualizza R Pastorello E 《Expert opinion on pharmacotherapy》2011,12(16):2527-2532
INTRODUCTION: The efficacy of venom immunotherapy (VIT) in patients with insect sting allergy is not questioned. However, its safety, especially when honeybee is used, is a matter of concern. AREAS COVERED: A systematic review of the literature on VIT was done, with both aqueous and depot extracts, to compare the frequency of systemic reactions to honeybee and vespid venoms. A Medline search was performed using the keywords 'venom immunotherapy', 'safety' and 'tolerability'. The articles obtained were analyzed regarding the total number of patients treated with either honeybee or vespid VIT, the number and severity of systemic reactions during therapy, the type of extract used (aqueous or depot) and the administration regimen. EXPERT OPINION: The incidence of systemic reactions to VIT was 25.1% for honeybee venom and 5.8% for vespid venom (p < 0.0001), while it was similar with aqueous and depot extracts in the whole population of patients. This confirms that during VIT systemic reactions are significantly more frequent with honeybee venom compared with vespid venom, while there are no significant overall differences in systemic reactions between aqueous and depot extracts. 相似文献
993.
Cancer is a leading cause of morbidity and mortality worldwide, with recent advancements resulting in modest impacts on patient survival. Nanomedicine represents an innovative field with immense potential for improving cancer treatment, having ushered in several established drug delivery platforms. Nanoconstructs such as liposomes are widely used in clinics, while polymer micelles are in advanced phases of clinical trials in several countries. Currently, the field of nanomedicine is generating a new wave of nanoscale drug delivery strategies, embracing trends that involve the functionalization of these constructs with moieties that enhance site-specific delivery and tailored release. Herein, we discuss several advancements in established nanoparticle technologies such as liposomes, polymer micelles, and dendrimers regarding tumor targeting and controlled release strategies, which are being incorporated into their design with the hope of generating a more robust and efficacious nanotherapeutic modality. We also highlight a novel strategy known as multistage drug delivery; a rationally designed nanocarrier aimed at overcoming numerous biological barriers involved in drug delivery through the decoupling of various tasks that comprise the journey from the moment of systemic administration to arrival at the tumor site. 相似文献
994.
Franchin G Vaccher E Talamini R Politi D Gobitti C Minatel E Lleshi A Sartor G Mascarin M Rumeileh IA Trovò MG Barzan L 《Oral oncology》2011,47(9):905-909
To evaluate the outcome of Undifferentiated Nasopharyngeal Carcinomas (UCNT) treated with intensity-modulated radiation therapy with Simultaneous Integrated Boost (SIB), following induction chemotherapy. Between January 2006 and June 2009, 52 patients with stage II B-IVA/B UCNT were treated either with linac-IMRT or Tomotherapy. All patients were scheduled to receive three cycles of cisplatin based neoadjuvant chemotherapy. With a median follow-up of 38.5 months (range 12.3–64.1), 3 year overall survival (OS), disease-free survival (DFS), and DFS by T2a–2b and T3–T4-stage were 95.0%, 84.6%, 89.0%, and 78.0%, respectively. At multivariate analysis, none of the examined prognostic factors reported statistical significance. N-classification was not a significant predictive factor for either OS or development of distant metastases. T-stage alone had a borderline effect on DFS and development of metastases. No difference between Tomotherapy and linac-IMRT emerged in terms of loco-regional control and development of severe, acute, and late toxicities. The most significant severe, acute toxicities were grade 3 (32.7%) and grade 4 (7.7%) mucositis. No grades 3 and 4 late toxicities were observed. The most commonly observed late effect was xerostomia, 11.5% patients complained grade 2 xerostomia. The severity of grade 2 xerostomia diminished over time with only four patients not improving salivation. IMRT-SIB following neoadjuvant chemotherapy was very satisfactory in terms of local control, regional control, DFS and OS rates in patients with stage IIB to IVB UCNT. In our experience, adding concurrent chemotherapy to IMRT after neoadjuvant chemotherapy in loco-regional widespread disease resulted to be the indicated approach. 相似文献
995.
996.
Frazzi R Casali B Iori M Nicoli D Mammi C Merli F 《International journal of oncology》2011,38(3):677-684
Clusterin (also called APOJ, SGP-2, XIP8) has thus far been only partially characterized in lymphomas contrary to other types of cancer. Its expression has been reported only for anaplastic large cell lymphomas and, more recently, in mycosis fungoides. Here, we demonstrate an up-regulation of intracellular clusterin in Hodgkin's lymphoma (HL)-derived cell lines L-428, KM-H2 and L-540, caused by different stimuli such as IFN-γ, doxorubicin and X-rays. These stimuli are relevant for the pathophysiology and therapy of HL and represent a first step in the characterisation of this glycoprotein known to have a role in drug chemoresistance. p53 up-regulation accompanies increases in clusterin levels accordingly with the onset of apoptosis. We also show that the cells secrete more clusterin after treatment with doxorubicin, which is consistent with the observed intracellular increase. These observations suggested that the levels of circulating clusterin should also be measured in the peripheral blood from HL patients both at the time of diagnosis and after two cycles of chemotherapy. In a preliminary study on patient sera we observed that an increase in clusterin is correlated with positron emission tomography (PET) positivity after two cycles of chemotherapy. 相似文献
997.
998.
999.
Costenaro F Rodrigues TC Kater CE Auchus RJ Papari-Zareei M Czepielewski MA 《Arquivos brasileiros de endocrinologia e metabologia》2010,54(8):744-748
Congenital adrenal hyperplasia (CAH) resulting from 17α-hydroxylase/17,20-lyase deficiency is a rare autosomal recessive disease and the second most common form of CAH in Brazil. We describe the case of a Brazilian patient with CYP17 deficiency (17α-hydroxylase/17,20-lyase deficiency) caused by a homozygous p.R96W mutation on exon 1 of the CYP17 gene, an unusual genotype in Brazilian patients with this form of CAH. The patient, raised as a normal female, sought medical care for lack of pubertal signs and primary amenorrhea at the age of 16 years. At evaluation, the presence of a 46,XY karyotype, hypertension and hypokalemia were observed. We emphasize the recognition of CYP17 deficiency in the differential diagnosis of cases of hypergonadotrophic hypogonadism and hypertension in young patients who need specific treatment for both situations. 相似文献
1000.
The appreciation that the inflammatory reaction does not ‘spontaneously’ finish, but rather that inflammatory resolution is an active phenomenon brought about by endogenous anti-inflammatory agonists opens multiple opportunities for a reassessment of the complexity of inflammation and its main mediators. This review dwells on one of these pathways, the one centred around the glucocorticoid-regulated protein Annexin A1 and its G protein-coupled receptor. In recent years, much of the knowledge detailing the processes by which Annexin A1 expresses its anti-inflammatory role on innate immunity has been produced. Moreover, the generation of the Annexin A1 null mouse colony has provided important proof-of-concept experiments demonstrating the inhibitory properties of this mediator in the context of inflammatory and/or tissue-injury models. Therefore, Annexin A1 acts as a pivotal homeostatic mediator, where if absent, inflammation would overshoot and be prolonged. This new understanding scientific information could guide us onto the exploitation of the biological properties of Annexin A1 and its receptor to instigate novel drug discovery programmes for anti-inflammatory therapeutics. This line of research relies on the assumption that anti-inflammatory drugs designed upon endogenous anti-inflammatory mediators would be burdened by a lower degree of secondary effects as these agonists would be mimicking specific pathways activated in our body for safe disposal of inflammation. We believe that the next few years will produce examples of such new drugs and the validity of this speculation could then be assessed.This article is part of a themed issue on Mediators and Receptors in the Resolution of Inflammation. To view this issue visit http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009 相似文献